Tobacco industry’s ‘wellness’ tactic: Ethical dilemma and solutions

Abstract

In recent years, tobacco companies have been investing in or acquiring pharmaceutical companies, which produce medications for a myriad of diseases, including tobacco-induced conditions and diseases, and emergency medicine. This results in ethical dilemmas – tobacco companies profit from selling medicines for health conditions, many of which are caused by tobacco products themselves. This article highlights some of these pharmaceutical acquisitions, the fundamental issues related to the same, and offers policy solutions in line with the global tobacco control treaty